Specify a stock or a cryptocurrency in the search bar to get a summary
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
688192Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China. Address: 199 Liangjing Rd, Shanghai, China, 201203
Analytics
WallStreet Target Price
390.56 CNYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688192
Dividend Analytics 688192
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 688192
Stock Valuation 688192
Financials 688192
Results | 2019 | Dynamics |